HC Wainwright Brokers Lower Earnings Estimates for TRDA

Key Points

• HC Wainwright has significantly downgraded its Q3 2025 earnings per share estimate for Entrada Therapeutics from ($1.05) to ($1.11), reflecting a pessimistic outlook for the company's financial performance.
• In a separate report, Wall Street Zen has revised Entrada Therapeutics' rating from "hold" to "sell," indicating a lack of confidence in the stock's future performance.
• Entrada's stock is currently trading at $5.19, down 2.1%, with recent earnings results showing a miss on EPS and revenue expectations, further highlighting financial struggles.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Analysts at HC Wainwright reduced their Q3 2025 earnings per share estimates for shares of Entrada Therapeutics in a report released on Thursday, August 7th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.11) per share for the quarter, down from their previous estimate of ($1.05). HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2026 earnings at ($4.64) EPS.

Separately, Wall Street Zen lowered Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Entrada Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.67.

Entrada Therapeutics Trading Down 3.4%

TRDA stock traded down $0.18 during trading hours on Monday, hitting $5.14. 42,810 shares of the stock traded hands, compared to its average volume of 148,093. Entrada Therapeutics has a one year low of $4.93 and a one year high of $21.79. The company has a market cap of $195.51 million, a P/E ratio of -2.89 and a beta of -0.12. The stock has a 50-day simple moving average of $6.72 and a 200 day simple moving average of $8.86.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.18). Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. The business had revenue of $1.98 million for the quarter, compared to analyst estimates of $8.17 million.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio increased its stake in Entrada Therapeutics by 6.2% during the 4th quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company's stock worth $298,000 after acquiring an additional 1,000 shares during the period. ExodusPoint Capital Management LP increased its stake in Entrada Therapeutics by 7.3% during the 4th quarter. ExodusPoint Capital Management LP now owns 16,453 shares of the company's stock worth $284,000 after acquiring an additional 1,113 shares during the period. WCG Wealth Advisors LLC increased its stake in Entrada Therapeutics by 6.2% during the 4th quarter. WCG Wealth Advisors LLC now owns 24,030 shares of the company's stock worth $415,000 after acquiring an additional 1,406 shares during the period. Martingale Asset Management L P boosted its holdings in shares of Entrada Therapeutics by 4.0% in the 1st quarter. Martingale Asset Management L P now owns 40,163 shares of the company's stock valued at $363,000 after purchasing an additional 1,540 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Entrada Therapeutics by 4.9% in the 4th quarter. Bank of America Corp DE now owns 35,721 shares of the company's stock valued at $618,000 after purchasing an additional 1,660 shares in the last quarter. Institutional investors own 86.39% of the company's stock.

Insider Transactions at Entrada Therapeutics

In other news, Director Kush Parmar sold 27,000 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $202,500.00. Following the completion of the transaction, the director directly owned 1,093,313 shares of the company's stock, valued at $8,199,847.50. This represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $52,012.50. Following the transaction, the insider directly owned 1,093,313 shares of the company's stock, valued at $8,199,847.50. This represents a 0.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 254,000 shares of company stock valued at $1,782,000 in the last quarter. 8.11% of the stock is currently owned by corporate insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.